124 related articles for article (PubMed ID: 34735158)
1. Discovery of (
Lv Q; Pan X; Wang D; Rong Q; Ma B; Xie X; Zhang Y; Wang J; Hu L
J Med Chem; 2021 Dec; 64(23):17184-17208. PubMed ID: 34735158
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy.
Lv Q; Yang H; Wang D; Zhou H; Wang J; Zhang Y; Wu D; Xie Y; Lv Y; Hu L; Wang J
J Med Chem; 2024 Apr; 67(8):6854-6879. PubMed ID: 38593344
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Urea Derivatives of Celastrol as Selective Peroxiredoxin 1 Inhibitors against Colorectal Cancer Cells.
Li Y; Zhu Y; Shang FF; Xu L; Jiang D; Sun B; Zhang L; Luo C; Zhang A; Zhang H; Ding C
J Med Chem; 2024 May; 67(9):7176-7196. PubMed ID: 38679872
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
5. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
[TBL] [Abstract][Full Text] [Related]
6. The c.1085A>G Genetic Variant of
Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
[No Abstract] [Full Text] [Related]
7. Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model.
Lee KH; Yen WC; Lin WH; Wang PC; Lai YL; Su YC; Chang CY; Wu CS; Huang YC; Yang CM; Chou LH; Yeh TK; Chen CT; Shih C; Hsieh HP
J Med Chem; 2021 Oct; 64(19):14477-14497. PubMed ID: 34606263
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.
Xie XX; Li H; Wang J; Mao S; Xin MH; Lu SM; Mei QB; Zhang SQ
Bioorg Med Chem; 2015 Oct; 23(19):6477-85. PubMed ID: 26321603
[TBL] [Abstract][Full Text] [Related]
9. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
[TBL] [Abstract][Full Text] [Related]
10. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
[TBL] [Abstract][Full Text] [Related]
11. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer.
Kulkarni A; Chandrasekar V; Natarajan SK; Ramesh A; Pandey P; Nirgud J; Bhatnagar H; Ashok D; Ajay AK; Sengupta S
Nat Biomed Eng; 2018 Aug; 2(8):589-599. PubMed ID: 30956894
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CSF-1R supports T-cell mediated melanoma therapy.
Sluijter M; van der Sluis TC; van der Velden PA; Versluis M; West BL; van der Burg SH; van Hall T
PLoS One; 2014; 9(8):e104230. PubMed ID: 25110953
[TBL] [Abstract][Full Text] [Related]
13. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent ureido tetrahydrocarbazole derivatives for cancer treatments through targeting tumor-associated macrophages.
Pei H; Qin J; Wang F; Tan B; Zhao Z; Peng Y; Yu F; Li E; Liu M; Zhang R; Liu B; Du B; Chen Y
Eur J Med Chem; 2019 Dec; 183():111741. PubMed ID: 31605873
[TBL] [Abstract][Full Text] [Related]
15. A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells.
Haegel H; Thioudellet C; Hallet R; Geist M; Menguy T; Le Pogam F; Marchand JB; Toh ML; Duong V; Calcei A; Settelen N; Preville X; Hennequi M; Grellier B; Ancian P; Rissanen J; Clayette P; Guillen C; Rooke R; Bonnefoy JY
MAbs; 2013; 5(5):736-47. PubMed ID: 23924795
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Potent and Selective FLT3 Inhibitor (
Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
[TBL] [Abstract][Full Text] [Related]
17. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
[TBL] [Abstract][Full Text] [Related]
18. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity.
Li XY; Zhang TJ; Kamara MO; Lu GQ; Xu HL; Wang DP; Meng FH
Cell Death Dis; 2019 Jul; 10(7):532. PubMed ID: 31296849
[TBL] [Abstract][Full Text] [Related]
20. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
Stafford JH; Hirai T; Deng L; Chernikova SB; Urata K; West BL; Brown JM
Neuro Oncol; 2016 Jun; 18(6):797-806. PubMed ID: 26538619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
